일부 문헌 자료에서는 CD6 리간드(CD6L)라고도 언급하고 있습니다.활성 T 세포, 활성 단구, 상피 세포, 섬유아세포, 뉴런, 흑색종 세포 및 땀과 [citation needed]피지선에서 발현됩니다.전이성 흑색종에서 유래한 세포주 내에서 [7]CD166 단백질 발현이 상향 조절되는 것으로 보고되었다.CD166은 흉선상피세포와 CD6+[citation needed]세포 사이의 부착 상호작용을 매개하는 중요한 역할을 한다.
Skonier JE, Bowen MA, Emswiler J, et al. (1996). "Recognition of diverse proteins by members of the immunoglobulin superfamily: delineation of the receptor binding site in the human CD6 ligand ALCAM". Biochemistry. 35 (38): 12287–91. doi:10.1021/bi961038k. PMID8823162.
Singer NG, Mitra R, Lialios F, et al. (1998). "CD6 dependent interactions of T cells and keratinocytes: functional evidence for a second CD6 ligand on gamma-interferon activated keratinocytes". Immunol. Lett. 58 (1): 9–14. doi:10.1016/S0165-2478(97)02707-7. PMID9436462.
Cortés F, Deschaseaux F, Uchida N, et al. (1999). "HCA, an immunoglobulin-like adhesion molecule present on the earliest human hematopoietic precursor cells, is also expressed by stromal cells in blood-forming tissues". Blood. 93 (3): 826–37. doi:10.1182/blood.V93.3.826. PMID9920831.
Tomita K, van Bokhoven A, Jansen CF, et al. (2000). "Coordinate recruitment of E-cadherin and ALCAM to cell-cell contacts by alpha-catenin". Biochem. Biophys. Res. Commun. 267 (3): 870–4. doi:10.1006/bbrc.1999.2040. PMID10673383.
Kristiansen G, Pilarsky C, Wissmann C, et al. (2003). "ALCAM/CD166 is up-regulated in low-grade prostate cancer and progressively lost in high-grade lesions". Prostate. 54 (1): 34–43. doi:10.1002/pros.10161. PMID12481253. S2CID22749852.
Zhang H, Li XJ, Martin DB, Aebersold R (2003). "Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry". Nat. Biotechnol. 21 (6): 660–6. doi:10.1038/nbt827. PMID12754519. S2CID581283.
Verma A, Shukla NK, Deo SV, et al. (2005). "MEMD/ALCAM: a potential marker for tumor invasion and nodal metastasis in esophageal squamous cell carcinoma". Oncology. 68 (4–6): 462–70. doi:10.1159/000086989. PMID16024937. S2CID25355369.